## **Special Issue**

## Non-communicable Diseases, Big Data and Artificial Intelligence

### Message from the Guest Editors

The 2030 Agenda for Sustainable Development adopted by the United Nations in 2015 recognized noncommunicable diseases (NCDs) as a major public health challenge. NCDs are usually multifactorial diseases influenced by both genetic and environmental factors, which makes them difficult to prevent and treat effectively. Medical and health big data consisting of lifestyle, clinical, and biological data provide an almost unlimited amount of information about diseases, far exceeding the human ability to make sense of it. Artificial intelligence (AI) offers the potential to analyze large and complex datasets in order to improve predicative, preventive, and personalized medicine (3P) medicine). This Special Issue plans to give an overview of the most recent advances in the field of Al and their application potential in 3P medicine. Potential topics include, but are not limited to:

- Cutting edge advances in AI in terms of medical and health big data.
- Application of AI in risk stratifying of diseases.
- Risk factor screening using Al.
- Application of AI in diagnosis.
- Application of AI in prognosis.
- Evaluation of the therapeutic effects of using Al.

#### **Guest Editors**

Prof. Dr. Youxin Wang

Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing 100069, China

Dr. Ming Feng

Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China

### Deadline for manuscript submissions

closed (30 June 2022)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



### mdpi.com/si/97322

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



### About the Journal

### Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

### **Editor-in-Chief**

### Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

